

# Gordon MacGregor

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6441683/publications.pdf>

Version: 2024-02-01

8  
papers

659  
citations

1478505

6  
h-index

1720034

7  
g-index

8  
all docs

8  
docs citations

8  
times ranked

992  
citing authors

#	ARTICLE	IF	CITATIONS
1	Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. <i>Science</i> , 2016, 354, 751-757.	12.6	462
2	Stepwise pathogenic evolution of <i>Mycobacterium abscessus</i> . <i>Science</i> , 2021, 372, .	12.6	91
3	Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 267-277.	10.7	66
4	Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study. <i>ERJ Open Research</i> , 2020, 6, 00132-2020.	2.6	17
5	Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial. <i>PLoS ONE</i> , 2020, 15, e0242945.	2.5	10
6	Patterns and Impact of Hypoglycemia, Hyperglycemia, and Glucose Variability on Inpatients with Insulin-Treated Cystic Fibrosis-Related Diabetes. <i>Diabetes Therapy</i> , 2016, 7, 575-582.	2.5	9
7	Tezacaftor-ivacaftor use in routine care of adults with cystic fibrosis: a medicine use evaluation. <i>European Journal of Hospital Pharmacy</i> , 2023, 30, 142-146.	1.1	4
8	P061â€¦The prevalence and monitoring of cirrhotic and non-cirrhotic cystic fibrosis liver disease in an adult West of Scotland cohort. , 2021, , .		0